Mammalian cell expression systems are the most commonly used platforms for producing biotherapeutic proteins. However, development of recombinant mammalian cell lines is often hindered by the unstable and variable transgene expression associated with random integration.
The recent PLOS publication describes how mammalian master cell lines were established with a landing pad engineered at the Hipp11 (H11) locus. We identified the H11 locus to be a "safe harbor" locus for gene knock-in in CHO-S cells. The landing pad placed at the H11 locus includes a pair of PhiC31 bacteriophage attP sites and genes facilitating integrase-based transgene integration.
Dr. Ruby Yanru Chen-Tsai, co-founder and CSO at ASC, and co-inventor of the TARGATT™ technology, stated: “ASC has developed an efficient strategy for site-specific integration of large genes of interest. This method enables rapid and precise insertion of a single copy gene expression cassette at defined loci in mammalian cells, resulting in homogeneous transgene expression. We have successfully applied our core technology to CHO and HEK293T mammalian cell lines for bioproduction applications. These cell lines will allow for fast and efficient bioproduction cell line generation in as fast as 3 months.”
ASC has also successfully employed the TARGATT™ technology in custom animal model generation service to allow the generation of site-specific knock-in animal models for a variety of research applications. In addition to CHO-S and HEK293T cell lines, ASC also offers products including the docking-site ready TARGATT™ “attP” mice, transgenic kits and plasmids for mouse model engineering in your own animal facilities. This technology is currently available for licensing.
For further details regarding licensing of this technology and service/ product offerings, please contact ASC at firstname.lastname@example.org.
About Applied StemCell, Inc.
Applied StemCell, Inc. is a fast-growing biotechnology company with more than 10 years’ experience in genome editing and stem cell technologies. Our mission is to advance genome editing technology innovation to develop more efficacious and safer gene and cell therapies. Applied StemCell has raised $63 million US dollars in support of their gene and cell therapy and other research programs.